Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
AMI to become part of Enpro’s Sealing Technologies Segment
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
The unit’s contribution to the company's revenue US$3.85 million in the last fiscal year
Sirius JV will be owned 51% by Sirius and 49% by Adani
Marks remarkable acceleration in innovation using AI technology
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Subscribe To Our Newsletter & Stay Updated
